Loading...
Market
Will major insurance plans cover psilocybin therapy by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from major insurance providers and healthcare policy updates
Story
Psilocybin Therapy Cuts Depression by Over 70% in COVID Healthcare Workers
Dec 5, 2024, 04:07 PM
A study published by the American Medical Association has found that psilocybin therapy, derived from magic mushrooms, led to a significant and sustained reduction in symptoms of depression among frontline healthcare workers, including doctors and nurses, who served during the COVID-19 pandemic. The therapy reduced depression scores by over 70%, compared to a 30% reduction observed with a placebo. Participants experienced an average drop in depression scores, underscoring the potential of psilocybin as a therapeutic option for mental health challenges faced by healthcare professionals.
View original story
Similar markets
Yes • 50%
No • 50%
Long-term mental health effects • 25%
Regulatory challenges • 25%
Ethical considerations • 25%
Lack of conclusive evidence • 25%
Yes • 50%
No • 50%
Oregon • 25%
Colorado • 25%
Washington • 25%
Other • 25%
Increased funding • 25%
Same level of funding • 25%
Decreased funding • 25%
No funding • 25%
Yes • 50%
No • 50%
2 or fewer states • 25%
3-5 states • 25%
6-10 states • 25%
More than 10 states • 25%
Yes • 50%
No • 50%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
